Navigation Links
Senetek PLC Reports First Quarter 2008 Financial Results
Date:5/15/2008

Agreement in Principle Reached to Terminate Marketing Agreement with Triax

Aesthetics, LLC for Pyratine-6(TM) on Most Favorable Terms

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced financial results for the quarter ended March 31, 2008 and an agreement in principle to terminate its marketing agreement with Triax Aesthetics, LLC ("Triax") for Pyratine-6(TM) on most favorable terms.

Revenue for the quarter ended March 31, 2008 was $441,000, compared with $25,308,000 reported in the first quarter of 2007. Revenues for the first quarter of 2007 included $24,750,000 recognized in conjunction with the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc.

Net loss for the quarter ended March 31, 2008 totaled $1,757,000, a loss of $0.23 per share compared to a net income of $21,733,000 or $2.85 per share in the first quarter of 2007. Net loss for the quarter ended March 31, 2008 included $926,000 of sales and marketing fee expense to Triax. Net income for the quarter ended March 31, 2007 included the effect of the previously announced grant of a paid up license for Kinetin and Zeatin to Valeant Pharmaceuticals Inc. and $1,320,000 from settlement of claims against a professional services provider for past performance related matters.

The Company has reached an agreement in principle, subject to receipt of certain documentation and information, to terminate its marketing agreement with Triax for Pyratine-6(TM) on most favorable terms. These terms would include the return of $1,125,000 in cash from Triax and a service provider, return of all intellectual property, product inventory and promotional materials, access and ownership of all accounts opened, a non-competition agreement from Triax and certain related parties prohibiting them from selling any topical cosmetic non monograph products used for antiaging purpose and/or in connection with acne rosacea for a period of two years, along with rights to utilization of the "Triax Aesthetics" name in conjunction with the sales of existing packaged product inventory. The termination agreement is expected to be finalized shortly.

The Company will announce the date and time of a teleconference call for investors when the agreement to terminate its marketing agreement with Triax is finalized.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces Appointments of Key Personnel
2. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
3. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
4. China Biologic Products Reports First Quarter 2008 Results
5. Escalon(R) Reports Third Quarter Fiscal 2008 Results
6. Cadus Reports First Quarter 2008 Results
7. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
8. SPO Medical Reports First Quarter 2008 Results
9. Nile Therapeutics Reports 2008 First Quarter Financial Results
10. Derma Sciences Reports First Quarter 2008 Results
11. NeurogesX Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... San Diego, CA (PRWEB) , ... August 15, ... ... science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the ... reduces the number of steps needed to gain kinetic binding data for a ...
(Date:8/15/2017)... NY (PRWEB) , ... August 15, 2017 , ... ... first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and ... held February 7-9, 2018, at The Roosevelt Hotel in New York City. , “With ...
(Date:8/14/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the release of SYZYGY™, a new open standard for connecting high-performance peripherals to ... low cost, low pin-count, high-performance connectivity solution between FPGAs and single-purpose hardware peripherals. ...
(Date:8/11/2017)... ... 2017 , ... Algenist continues to disrupt the skincare industry with today’s debut ... , Collagen is the key structural element skin needs to maintain its youthful appearance ... First to market with proprietary collagen water active , ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):